Novo Nordisk Pharma Korea said it has expanded the sales of Saxenda (ingredient: liraglutide 3.0 mg), an obesity treatment as a glucagon-like peptide 1 receptor agonist, to 10 general hospitals, including Seoul National University Hospital (SNUH).
Released in March, the drug is now available at 10 general hospitals, including SNUH, Bundang Seoul National University Hospital, Severance Hospital, Kangbuk Samsung Hospital, Ajou University Hospital, and Soon Chun Hyang University Hospital Seoul.
The drugmaker said it aimed to provide Saxenda for more than 15 hospitals within the first half, by persuading each hospital’s pharmaceutical committee to allow the purchase of the drug.
“Saxenda was launched in Korea for the first time in Asia. Within the first two months of the release, 10 major hospitals have decided to use the treatment. We plan to expand the target hospitals continuously,” said Rana Asfar, general manager of Novo Nordisk Pharma Korea.
“We will also make our best effort to improve social awareness on obesity and the importance of proper obesity management,” he added.
<© Korea Biomedical Review, All rights reserved.>